Molecule-1

Molecule-1 is an experimental small molecule hybrid designed as a histone deacetylase (HDAC) inhibitor for the treatment of cancer. It was developed to address the toxicity and poor pharmacokinetic properties of traditional hydroxamate-based HDAC inhibitors, such as vorinostat, by incorporating natural antioxidant pharmacophores into its structure. The molecule aims to provide antineoplastic activity through epigenetic modulation, specifically by inhibiting HDAC enzymes to reactivate tumor suppressor genes. Its design was guided by in silico studies and molecular docking to optimize binding affinity and selectivity toward the HDAC catalytic site while potentially improving the safety profile compared to first-generation agents.